Given the critical roles that VHL and VEGF pathways play in RCC tumorigenesis and anti-tumor immunity, studies have been surprisingly ambiguous in terms of the utility of these biomarkers for predicting response to ICIs. This evidence concerns the gene VEGFA and neoplasm.